---
title: 'Genentech, Immunocore, Biogen, Eli Lilly, TenSixteen'
type: 'episode'
url: 'https://doc.social/episodes/genentech-immunocore-biogen-eli-lilly-tensixteen'
show: 'Life Science Today'
show_url: 'https://doc.social/podcasts/life-science-today'
published: '2022-02-02'
audio: 'unavailable — the host retired the file'
---

# Genentech, Immunocore, Biogen, Eli Lilly, TenSixteen

Bispecific antibodies, ocular oncology, Biogen sells, Lilly Builds, and the treatment of a lifetimeFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesGenentechImmunocoreBiogenEli LillyTenSixteenAbout the ShowLife Science Tod…

## Summary

Bispecific antibodies, ocular oncology, Biogen sells, Lilly Builds, and the treatment of a lifetime

**Find out more at
**[https://LifeScienceTodayPodcast.com
](https://lifesciencetodaypodcast.com/)
**Story References
**[Genentech](https://www.biospace.com/article/releases/fda-approves-genentech-s-vabysmo-the-first-bispecific-antibody-for-the-eye-to-treat-two-leading-causes-of-vision-loss/?s=74)
[Immunocore](https://www.biospace.com/article/releases/immunocore-announces-fda-approval-of-kimmtrak-tebentafusp-tebn-for-the-treatment-of-unresectable-or-metastatic-uveal-melanoma/?s=74)
[Biogen](https://www.biospace.com/article/biogen-sells-2-3-billion-stake-in-samsung-bioepis/?s=79)
[Eli Lilly
](https://investor.lilly.com/news-releases/news-release-details/lilly-announces-1-billion-investment-new-manufacturing-facility)[TenSixteen](https://www.biospace.com/article/tensixteen-scores-40m-to-intercept-disease-at-its-earliest-stages-/?s=80)**

**
**About the Show
**Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.